nach oben

Medical Oncology

Erschienen in:

01.06.2012 | Original Paper

Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients

verfasst von: Irena Ranogajec, Jasminka Jakić-Razumović, Velibor Puzović, Jelka Gabrilovac

Erschienen in: Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to analyse the expression of matrix metalloproteinase-2(MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase APN/CD13 in breast carcinoma samples, and their possible prognostic value in breast cancer patients. The expression of MMP-2, MMP-9 and APN/CD13 in tumor cells was analysed in 138 breast carcinomas by immunohistochemical staining of tumor cells using the semiquantitative method for the detection of cytoplasmic and membrane reaction in tumor cells as well as stromal cells positivity. MMP-2 was positive in tumor cells of 52.9% patients and in stromal cells of 74.6% patients, while MMP-9 positive tumor and stromal cells were found in 84.8 and 63.8% patients, respectively. Tumor cell APN/CD13 expression was found in 36.2% patients. Stromal cell MMP-2 expression correlated significantly with tumor size and neoangiogenesis. A positive correlation was also observed between tumor cell MMP-9 expression and hormone receptor status. Stromal cell coexpression of MMP-2/MMP-9 correlated significantly with tumor size. APN/CD13 expression in tumor cells significantly correlated with tumor type and neoangiogenesis. Overall survival was significantly shorter in patients with MMP-2, MMP-2/MMP-9 positive tumor cells, and tended to be shorter in patients with APN/CD13 positive tumor cells. Coexpression of MMP-2/MMP-9 in tumor cells was an independent risk factor for patient survival (OD = 13.9). Our results suggest that MMP-2, MMP-9, APN/CD13 expression and MMP-2/MMP-9 coexpression in combination with other standard prognostic factors can serve as a poor prognostic factor in the evaluation of breast cancer prognosis.

Strnad M, Hrabak-Žerjavić V, Šamija M. Epidemiology, prevention and early detection of breast cancer. In: Šamija M, Juzbašić S, Šeparović V, Vrdoljak VD, editors. Breast tumors. 1st ed. Zagreb: Medicinska Naklada; 2007. p. 27–32.

Lester SC, Cotran RS. The breast. In: Cotran RS, Kumar V, Robbins SLG, editors. Pathologic basis of disease. 6th ed. Philadelphia: WB Sounders; 1999. p. 1093–119.

Rosen PP. Invasive duct carcinoma, assessment of prognosis, morphologic prognostic markers and tumor growth rate. In: Rosen PP, editor. Rosen’s breast pathology. 2nd ed. Philadelphia: Lippincott Williams/Wilkins; 2001. p. 325–56.

Woessner JF, Nagase H. Matrix metalloproteinases and TIMPs (protein profile). 2nd ed. In: Woessner JF, Nagase H, editors. New York: Oxford University Press; 2000.

Duffy MJ, Maguire TM, Hill A, McDermott E, Ohiggins N. Metalloproteinases: role in breast cancerogenesis, invasion and metastasis. Br Cancer Res. 2000;4:252–7.CrossRef

Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function and biochemistry. Circ Res. 2003;2:827–39.CrossRef

Ross JS, Linette GP, Stec J, Clark E, Ayers M, et al. Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn. 2004;2:169–88.CrossRef

John A, Tuszynski G. The role of matrix metalloproteinases in tumour angiogenesis and tumor metastasis. Pathol Oncol Res. 2001;7:14–23.PubMedCrossRef

Tsukamoto H, Shibata K, Kajiyama H, Terauchi M, Nawa A, Kikkawa F. Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer. BMC Cancer. 2008;8:74–80.PubMedCrossRef

10.

Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer. 2007;7:140–6.PubMedCrossRef

11.

Caudroy S, Polette M, Tournier JM, Burlet H, Toole B, Zucker S, Birembaut P. Expression of the extracellular matrix metallo-proteinase inducer (EMMPERIN) and the matrix metalloproteinase-2 in bronchopulmonary and breast lesions. J Histochem Cytochem. 1999;47:1575–80.PubMedCrossRef

12.

van Hensbergen Y, Broxterman HJ, Rana S, van Diest PJ, Duyndam MCA, et al. Reduced growth, increased vascular area and reduced response to Cisplatin in CD13-overexpressing human ovarian cancer xenografts. Clin Cancer Res. 2004;10(3):1180–91.PubMedCrossRef

13.

Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH. CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood. 2001;97(3):652–9.PubMedCrossRef

14.

Yang E, Shim JS, Woo HJ, Kim KW, Kwon HJ. Aminopeptidase N/CD13 induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3. Biochem Biophys Res Commun. 2007;363:336–41.PubMedCrossRef

15.

Singer CF, Kronsteiner N, Marton E, Kubista M, Cullen KJ, et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Br Cancer Res. 2002;72:69–77.CrossRef

16.

Tetu B, Trudel D, Wang CS. Proteases by reactive stromal cells in cancer: an attractive therapeutic target. Bull Cancer. 2006;93(9):944–8.PubMed

17.

Szabo KA, Singh G. Modulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cells. Br Cancer Res. 2005;7:661–8.CrossRef

18.

Sellers A, Reynolds JJ, Meikle MC. Neutral metallo-proteinases of rabbit bone. Separation in in latent forms of distinct enzymes that when activated degrade collagen, gelatin and proteoglycans. Biochem J. 1978;171:493–6.PubMed

19.

Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase-2 (MMP-2) and MMP-9 in breast cancer with a special reference to activator protein-2, Her2, and prognosis. Clin Cancer Res. 2004;10:7621–8.PubMedCrossRef

20.

Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin Cancer Res. 2004;3:1057–63.CrossRef

21.

Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem. 1990;265:11077–82.PubMed

22.

Peihong S, Perry F. Expression of nm23, MMP-2, TIMP-2 in breast neoplasm in Zhen-Zhou Center Hospital, China. Ethio Med J. 2007;45:79–83.

23.

Ogura S, Ohdaira T, Hozumi Y, Omoto Y, Nagai H. Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk. J Surg Oncol. 2007;96:46–53.PubMedCrossRef

24.

Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma. Br Cancer Res Treat. 1999;58:287–93.CrossRef

25.

Fan SQ, Wei QY, Li MR, Zhang LQ, Liang QC. Expression and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in breast carcinoma. Ai Zheng. 2003;22(9):968–73.PubMed

26.

Shah FD, Shukla SN, Shah PM, Shukla HK, Patel PS. Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer. 2009;46(3):194–202.PubMedCrossRef

27.

Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, et al. MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors. J Cell Mol Med. 2006;10(2):499–510.PubMedCrossRef

28.

Cao D, Polyak K, Halushka M, Nassar H, Kouprina N, et al. Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4, overexpression of matrix metalloproteinase 9. Br Caner Res. 2008;10:R91.CrossRef

29.

Liu SC, Yang SF, Yeh KT, Yeh CM, Chiou HL, et al. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer. Clin Chim Acta. 2006;371:92–6.PubMedCrossRef

30.

Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;6:1270–5.CrossRef

31.

Li HC, Cao DC, Liu Y, Hou YF, Wu J, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Br Cancer Res Treat. 2004;88:75–85.CrossRef

32.

Saiki I, Yoneda J, Azuma I, Fujii H, Abe F, Nakajima M, Tsuruo T. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer. 2006;54(1):137–43.CrossRef

33.

Martinez JM, Prieto I, Ramirez MJ, Cueva C, Alba F, Ramirez M. Amino peptidase activities in breast cancer tissue. Clin Chem. 1999;45(10):1797–802.PubMed

34.

Liang X, Zhao J, Hajivandi M, Wu R, Tao J, Amshey JW, Pope RM. Quantification of membrane and membrane-bound proteins in normal and malignant breast cancer cells isolated from the same patient with primary breast carcinoma. Proteome Res. 2006;5(10):2632–41.CrossRef

35.

Dixon J, Kaklamanis L, Turley H, Hickson ID, Leek RD, Harris AL, Gatter KC. Expression of aminopeptidase-N (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol. 1994;47(1):43–7.PubMedCrossRef

36.

Bogenrieder T, Finstad CL, Freeman RH, Papandreou CN, Scher HI, et al. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate. 1997;33(4):225–32.PubMedCrossRef

37.

Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H, Miyake M. Clinical significance of Aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res. 2003;9:1503–8.PubMed

38.

Tokuhara T, Hattori N, Ishida H, et al. Aminopeptidase N in non-small cell lung cancer. Clin Cancer Res. 2006;12:3971–8.PubMedCrossRef

39.

Kehlen A, Lendeckel U, Dralle H, Langner J, Hoang-Vu C. Biological significance of Aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res. 2003;63:8500–6.PubMed

40.

Hashida H, Takabayashi A, Kanai M, et al. Aminopeptidase N is involved in cell motility and angiogenesis: Its clinical significance in human colon cancer. Gastroenterology. 2002;122(2):376–86.PubMedCrossRef

41.

Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000;60(3):722–7.PubMed

42.

Garde SV, Forte AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13- expressing cells and its antitumor effects. Anticancer Drugs. 2007;18:1189–200.PubMedCrossRef

43.

Wickstrom M, Viktorsson K, Lundholm L, et al. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol. 2010;79(9):1281–90.PubMedCrossRef

Titel: Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients
verfasst von: Irena Ranogajec
Jasminka Jakić-Razumović
Velibor Puzović
Jelka Gabrilovac
Publikationsdatum: 01.06.2012
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 2/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-011-9984-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802

Correlation between T-cadherin gene expression and aberrant methylation of T-cadherin promoter in human colon carcinoma cells

Prognostic value of hedgehog signaling pathway in patients with colon cancer

Expression of GPC3 protein and its significance in lung squamous cell carcinoma

Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie